Cargando…

Suppression of nitric oxide production from nasal fibroblasts by metabolized clarithromycin in vitro

BACKGROUND: Low-dose and long-term administration of 14-membered macrolide antibiotics, so called macrolide therapy, has been reported to favorably modify the clinical conditions of chronic airway diseases. Since there is growing evidence that macrolide antibiotic-resistant bacteria's spreaders...

Descripción completa

Detalles Bibliográficos
Autores principales: Furuya, Ayako, Asano, Kazuhito, Shoji, Naruo, Hirano, Kojiro, Hamasaki, Taisuke, Suzaki, Harumi
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003651/
https://www.ncbi.nlm.nih.gov/pubmed/21092318
http://dx.doi.org/10.1186/1476-9255-7-56
_version_ 1782193884595486720
author Furuya, Ayako
Asano, Kazuhito
Shoji, Naruo
Hirano, Kojiro
Hamasaki, Taisuke
Suzaki, Harumi
author_facet Furuya, Ayako
Asano, Kazuhito
Shoji, Naruo
Hirano, Kojiro
Hamasaki, Taisuke
Suzaki, Harumi
author_sort Furuya, Ayako
collection PubMed
description BACKGROUND: Low-dose and long-term administration of 14-membered macrolide antibiotics, so called macrolide therapy, has been reported to favorably modify the clinical conditions of chronic airway diseases. Since there is growing evidence that macrolide antibiotic-resistant bacteria's spreaders in the populations received macrolide therapy, it is strongly desired to develop macrolide antibiotics, which showed only anti-inflammatory action. The present study was designed to examine the influence of clarithromycin (CAM) and its metabolized materials, M-1, M-4 and M-5, on free radical generation from nasal polyp fibroblasts (NPFs) through the choice of nitric oxide (NO), which is one of important effector molecule in the development of airway inflammatory disease in vitro. METHODS: NPFs (5 × 10(5 )cells/ml) were stimulated with 1.0 μg/ml lipopolysaccharide (LPS) in the presence of agents for 24 hours. NO levels in culture supernatants were examined by the Griess method. We also examined the influence of agents on the phosphorylation of MAPKs, NF-κB activation, iNOS mRNA expression and iNOS production in NPFs cultured for 2, 4, 8, and 12 hours, respectively. RESULTS: The addition of CAM (> 0.4 μg/ml) and M-4 (> 0.04 μg/ml) could suppress NO production from NPFs after LPS stimulation through the suppression of iNOS mRNA expression and NF-κB activation. CAM and M-4 also suppressed phosphorylation of MAPKs, ERK and p38 MAPK, but not JNK, which are increased LPS stimulation. On the other hand, M-1 and M-5 could not inhibit the NO generation, even when 0.1 μg/ml of the agent was added to cell cultures. CONCLUSION: The present results may suggest that M-4 will be a good candidate for the agent in the treatment of chronic airway inflammatory diseases, since M-4 did not have antimicribiological effects on gram positive and negative bacteria.
format Text
id pubmed-3003651
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30036512010-12-18 Suppression of nitric oxide production from nasal fibroblasts by metabolized clarithromycin in vitro Furuya, Ayako Asano, Kazuhito Shoji, Naruo Hirano, Kojiro Hamasaki, Taisuke Suzaki, Harumi J Inflamm (Lond) Research BACKGROUND: Low-dose and long-term administration of 14-membered macrolide antibiotics, so called macrolide therapy, has been reported to favorably modify the clinical conditions of chronic airway diseases. Since there is growing evidence that macrolide antibiotic-resistant bacteria's spreaders in the populations received macrolide therapy, it is strongly desired to develop macrolide antibiotics, which showed only anti-inflammatory action. The present study was designed to examine the influence of clarithromycin (CAM) and its metabolized materials, M-1, M-4 and M-5, on free radical generation from nasal polyp fibroblasts (NPFs) through the choice of nitric oxide (NO), which is one of important effector molecule in the development of airway inflammatory disease in vitro. METHODS: NPFs (5 × 10(5 )cells/ml) were stimulated with 1.0 μg/ml lipopolysaccharide (LPS) in the presence of agents for 24 hours. NO levels in culture supernatants were examined by the Griess method. We also examined the influence of agents on the phosphorylation of MAPKs, NF-κB activation, iNOS mRNA expression and iNOS production in NPFs cultured for 2, 4, 8, and 12 hours, respectively. RESULTS: The addition of CAM (> 0.4 μg/ml) and M-4 (> 0.04 μg/ml) could suppress NO production from NPFs after LPS stimulation through the suppression of iNOS mRNA expression and NF-κB activation. CAM and M-4 also suppressed phosphorylation of MAPKs, ERK and p38 MAPK, but not JNK, which are increased LPS stimulation. On the other hand, M-1 and M-5 could not inhibit the NO generation, even when 0.1 μg/ml of the agent was added to cell cultures. CONCLUSION: The present results may suggest that M-4 will be a good candidate for the agent in the treatment of chronic airway inflammatory diseases, since M-4 did not have antimicribiological effects on gram positive and negative bacteria. BioMed Central 2010-11-23 /pmc/articles/PMC3003651/ /pubmed/21092318 http://dx.doi.org/10.1186/1476-9255-7-56 Text en Copyright ©2010 Furuya et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Furuya, Ayako
Asano, Kazuhito
Shoji, Naruo
Hirano, Kojiro
Hamasaki, Taisuke
Suzaki, Harumi
Suppression of nitric oxide production from nasal fibroblasts by metabolized clarithromycin in vitro
title Suppression of nitric oxide production from nasal fibroblasts by metabolized clarithromycin in vitro
title_full Suppression of nitric oxide production from nasal fibroblasts by metabolized clarithromycin in vitro
title_fullStr Suppression of nitric oxide production from nasal fibroblasts by metabolized clarithromycin in vitro
title_full_unstemmed Suppression of nitric oxide production from nasal fibroblasts by metabolized clarithromycin in vitro
title_short Suppression of nitric oxide production from nasal fibroblasts by metabolized clarithromycin in vitro
title_sort suppression of nitric oxide production from nasal fibroblasts by metabolized clarithromycin in vitro
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003651/
https://www.ncbi.nlm.nih.gov/pubmed/21092318
http://dx.doi.org/10.1186/1476-9255-7-56
work_keys_str_mv AT furuyaayako suppressionofnitricoxideproductionfromnasalfibroblastsbymetabolizedclarithromycininvitro
AT asanokazuhito suppressionofnitricoxideproductionfromnasalfibroblastsbymetabolizedclarithromycininvitro
AT shojinaruo suppressionofnitricoxideproductionfromnasalfibroblastsbymetabolizedclarithromycininvitro
AT hiranokojiro suppressionofnitricoxideproductionfromnasalfibroblastsbymetabolizedclarithromycininvitro
AT hamasakitaisuke suppressionofnitricoxideproductionfromnasalfibroblastsbymetabolizedclarithromycininvitro
AT suzakiharumi suppressionofnitricoxideproductionfromnasalfibroblastsbymetabolizedclarithromycininvitro